Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol®

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).

Cipla's Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation's Durezol®.

It is used for the following:

- Treatment of inflammation and pain associated with ocular surgery.
- Treatment of endogenous anterior uveitis.

According to IQVIA (IMS Health), Durezol® had US sales of approximately $106mn for the 12-month period ending June 2021.

The product will be available for shipping soon.

Shares of Cipla Ltd., was last trading in BSE at Rs. 908.45 as compared to the previous close of Rs. 912.4. The total number of shares traded during the day was 321893 in over 4387 trades.

The stock hit an intraday high of Rs. 915 and intraday low of 891.35. The net turnover during the day was Rs. 291605065.

Source : Equity Bulls

Keywords